CFO
GBIO

Callan Family Office’s Generation Bio GBIO Stock Holding History

Callan Family Office’s Portfolio GBIO Stock Details GBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-6,974
Closed -$22.3K – 891
2025
Q2 		$22.3K Buy
+6,974
New +$26.9K ﹤0.01% 912

Other funds holding GBIO

AVLSA
Atlas Venture Life Science Advisors Cambridge, Massachusetts $790M AUM 223.66% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Callan Family Office's GBIO Position: Q3 2025 in Review

Callan Family Office sold out of Generation Bio (GBIO) in Q3 2025, closing a stake of 6,974 shares — an estimated $22.3K sold.

Callan Family Office first reported a position in GBIO in Q2 2025 and held it in 1 quarter. The position peaked at $22.3K in Q2 2025. 41 funds tracked by Wall St. Rank hold GBIO as of Q3 2025.

  • Callan Family Office reported no remaining Generation Bio position as of Q3 2025 after selling out during the quarter.
  • Callan Family Office sold 6,974 Generation Bio shares in Q3 2025, an estimated $22.3K.
  • Callan Family Office first reported a position in Generation Bio in Q2 2025 and held it in 1 quarter.
  • Callan Family Office's Generation Bio position peaked at $22.3K in Q2 2025.
  • 41 funds tracked by Wall St. Rank held Generation Bio as of Q3 2025.

Based on Callan Family Office's 13F filing for Q3 2025, filed 4 Nov 2025.